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The relevance of a diagnosis 
In this thesis, we identified a novel homozygous mutation in MMP14 in two patients 
with a multisystem disorder (see Chapter 1) and subsequently confirmed its patho-
genicity at the cellular level (see Chapter 2). This enabled us to provide the patients 
with a final diagnosis: Winchester syndrome (WS). Although this diagnosis does not 
alter the therapy that the patients are currently receiving, it is nevertheless important 
for several reasons. Firstly, it becomes possible to provide the patients with adequate 
information about their disorder and the underlying cause. This not only helps the 
patients in understanding of, but may also improve coping with their symptoms [1, 2]. 
Secondly, a diagnosis can focus additional examinations based on tissues and organ 
systems known to be involved in the particular disorder. Third, as WS is an autosomal 
recessive disorder, confirming the molecular diagnosis provides the opportunity to 
offer more precise genetic counselling to the patients (and partners), informing them 
about inheritance and the potential risk to their future offspring [1].  
 
The value of investigating rare genetic disorders 
WS is an ultra-rare autosomal recessive disorder; the molecular diagnosis has only been 
confirmed in four patients worldwide [3-5, see Chapter 1]. The clinically overlapping 
and genetically related skeletal dysplasias Frank-Ter Haar syndrome (FTHS) and multi-
centric osteolysis, nodulosis, and arthropathy (MONA) only add a limited number of 
patients [6-9]. Spending significant amounts of time, effort and taxpayer’s money on 
investigating these rare disorders may, therefore, seem only to benefit a handful of 
affected patients. However, the power of studying rare monogenetic disorders lays not 
so much in the number of patients with that exact diagnosis, but rather in the unique 
opportunity the direct genotype-phenotype correlation offers to study more common 
pathological processes from a unique and yet unexplored angle. This approach has 
previously been demonstrated successful and has contributed to major advanced in 
various fields. For instance, many genes now known to regulate osteoblast and osteo-
clast differentiation and function, including Runx2, Msx2, Sox9, FGFR1-3, and ca-
thepsin K, were first identified by studying monogenetic disorders [10]. Moreover, 
studying rare monogenetic disorders can lead to the identification of novel therapeutic 
targets. By this, studying rare genetic disorders can be beneficial to patients suffering 
from more prevalent disorders [5].  
 
Winchester syndrome as a model for acne and reduced bone density 
WS is a skeletal dysplasia characterised by a progressive generalised reduction of bone 
density, thoracic kyphosis, craniofacial dysmorphology and severe nodulocystic acne 
with dermal fibrosis and excessive scar formation [3, 4]. We are therefore convinced 
that WS can accurately model reduced bone density and acne (scarring). As mentioned 
CHAPTER 7 
266 
above, there is significant clinical overlap between WS, FTHS, and MONA [6-9]. The 
protein products of the involved genes MMP14, SH3PXD2B, and MMP2, respectively, 
cooperate in extracellular matrix (ECM) remodelling and invasive cell motility (see 
Chapter 1) [9, 11-15]. As such, this led to innovative lines of research studying the 
pathogenesis of acne and reduced bone density from a novel angle.  
 
Acne affects a significant part of the population and novel therapeutic  
options are needed 
Acne vulgaris is the most common skin disorder in the world and one of the most 
common ailments overall. In developing countries, it affects almost 100% of adoles-
cents [16]. Although usually mild and self-limiting, it is a chronic disease that is typical-
ly present for many years. In addition, acne is moderate-to-severe in 15-20% of pa-
tients and often persists into adulthood, with an estimated prevalence of 12% in adult 
females [17]. Apart from physical symptoms that are present while acne is fulminant, 
including soreness, itching, and pain, moderate-to-severe acne can leave disfiguring 
scars [16, 18]. Furthermore, acne can have a large impact on the patient’s quality of life 
and is often associated with significant psychosocial morbidity such as self-
consciousness and anxiety in social interaction, even when the acne itself is compara-
tively mild [18]. This psychological burden can be explained by the involvement of 
directly visible skin and occurance during puberty, an age that is crucial for building 
confidence and self-esteem, while popular culture furthermore emphasises the im-
portance of flawless skin [18]. The psychosocial comorbidity moreover has been 
demonstrated to have a negative impact on school and work performance. In the US 
alone, it was estimated that annually over 3 billion dollars are lost to the costs of 
treatment and reduced productivity [16].  
Although mild acne can be effectively addressed with topical drugs, moderate-to-
severe disease requires systemic therapy to prevent excessive scar formation [18]. 
However, current treatment options are limited and their use restricted by their side 
effects [19, 20]. No novel drug classes are being developed for moderate-to-severe 
acne since there is a profound lack of insight into acne pathogenesis [21, 22]. As such, 
there is a significant unmet medical need.  
 
In vitro 3D-culture for development of novel anti-acne therapeutics 
As stressed above, novel anti-acne therapeutics need to be developed. Acne is charac-
terised by the presence of comedones, which are cystic sebaceous glands, accompanied 
by inflammation around these structures [18]. The sebaceous gland is in essence a 
hollow, branched mini-organ. For normal morphogenesis of branching structures, 
ECM remodelling is essential [23]. Our WS patients demonstrated defective ECM 
remodelling and moreover, have a loss-of-function mutation in MMP14 (see Chapter 
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2), a central player in pericellular ECM degradation [24]. This urged us to explore the 
possible involvement of disturbed lumen formation, as a consequence of impaired 
ECM remodelling, in the pathogenesis of acne. In a pilot study, we used a simple, well-
established in vitro 3D cell culture model to confirm a crucial role of MMP14 and 
SH3PXD2B in lumen formation by epithelial cells [25]. Moreover, we demonstrated 
that therapeutic plasma concentrations of 13-cis RA have a stimulatory effect on lu-
men formation (see Chapter 3). The latter further highlighted the suitability of this in 
vitro model for assessing the effects of drug treatment. These promising results led to 
two subsequent studies. Firstly, as part of a multi-million dollar industry collaboration 
with a major international cosmetics producer, the in vitro model used in our pilot 
study was further developed for use with sebocytes. As this was successful, this novel 
sebocyte 3D model was subsequently used to assess the effects of existing (e.g. 13-cis 
RA) and novel drugs on organoid formation and sebum production. Secondly, collab-
oration was started with the University of Dundee Drug Discovery Unit. This latter 
project highlighted the potential of this in vitro model: upscaling with semi-automated 
analysis for drug screening, as reported before [25].  
 
The zebrafish is a valuable model organism for skin research 
The aforementioned in vitro 3D cell culture model offers the possibility to study lumen 
formation and the effect of prospective therapeutic compounds thereon. However, 
other aspects of acne, such as scarring, are hard – if not impossible – to model in vitro. 
To study these aspects, ultimately an organismal model is needed. Although MMP14 
mutant and knockout (KO) mice have been previously generated, mice are unsuitable 
for drug screening for a variety of reasons, such as high cost and the consequent ina-
bility to analyse large numbers of animals. A more suitable model organism that does 
not have these limitations is the zebrafish [26, 27]. Besides its use in genetic studies, 
the zebrafish is a powerful model organism for skin research. Adult zebrafish have 
dermal scales that are covered by a non-keratinizing epidermis. In addition, zebrafish 
do not have sebaceous glands, but instead harbour mucous glands [28, 29]. Apart from 
these adaptations to aquatic life, the architecture of zebrafish skin is remarkably similar 
to that of mammals. Similar to humans, zebrafish epidermis consists of multiple cell 
layers that moreover correspond to their human counterparts including the stratum 
basale, spinosum and granulosum [28, 29]. The epidermis is separated from the under-
lying dermis, containing the scales, by a basement membrane zone. Another attractive 
feature of zebrafish is their rapid external embryonic development; zebrafish form a 
fully functional multi-layered skin in only six days [29]. During this process, zebrafish 
are optically transparent and hence suitable for live in vivo microscopy experiments. 
Moreover, wound healing in zebrafish skin follows a similar basic sequence of events 
compared to mammalian skin [29, 30]. The causative gene of WS is conserved between 
human and zebrafish and in this thesis, we presented the first mmp14a/b KO zebrafish 
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model (see Chapter 4). We furthermore demonstrated that the phenotype of our fish 
recapitulates key aspects of the human pathology, suggestive of defective collagen 
remodelling as the underlying central problem. Therefore, we believe our fish can 
serve as a useful in vivo model for cutaneous tissue remodelling and scarring and de-
signed a novel project to be carried out by the A*STAR Skin Research Institute of 
Singapore in collaboration with the NTU Lee Kong Chian School of Medicine. Within 
this project, which will commence in September 2018, collagen remodelling will be 
assessed during cutaneous wound repair in our mutant fish. Subsequently, this will be 
used as readout for the effect of different commercially available and newly generated 
therapeutics. As such, this model may lead to the development of novel strategies 
targeting acne scarring.  
 
Reduced bone density is an increasing problem 
The skeletal dysplasias, including the multicentric osteolyses WS, FTHS, and MONA, 
are a heterogeneous group of over 450 inheritable disorders characterised by a general-
ised abnormal growth and development of bone and cartilage [31, 32]. Although the 
individual dysplasias are rare, a recent study conducted in South America analysing 
over 1.5 million births demonstrated that collectively the prevalence of skeletal dyspla-
sia is 3.2 per 10,000 births [32]. A large number of skeletal dysplasias, including WS, 
present with reduced bone density [33]. In the general population, osteoporosis (de-
fined by bone mineral density more than 2.5 standard deviations below the average of 
a young adult) is an increasing worldwide problem [34]. In the Netherlands, the preva-
lence of osteoporosis has been estimated to encompass 431,400 people in 2015, the 
majority of which are postmenopausal women [35]. In this subgroup, about 40% is 
affected by osteoporosis [36]. A reduction in bone density increases the risk of frac-
tures: patients with osteoporosis have a lifetime risk for fractures of 40%, primarily of 
the spine, hip and wrist [34, 36]. These fractures often result in chronic pain and/or 
loss of mobility and autonomy, and can have a drastic effect on the patient’s quality of 
life [34, 36]. In addition, fractures of the hip and spine are associated with a significant 
mortality as a result of complications due to hospitalisation [36]. In 2010, the annual 
health care costs of osteoporosis-related fractures in the Netherlands amounted to 
nearly 200 million euros [34]. As the prevalence of osteoporosis increases with age and 
the Dutch population is ageing, the number of osteoporosis-related fractures and ac-
companying costs are expected to increase in the future [35, 36]. Although present 
therapies are efficient, most have side effects limiting their long-term adherence [36]. 
Therefore, development of novel therapeutics is needed.  
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Zebrafish are invaluable in bone research 
For the development of drugs targeting bone density, an organismal model is needed. 
The zebrafish is a well-established model organism for vertebrate development. 
Zebrafish form all major types of skeletal cells and tissues found in higher vertebrates 
including humans [37-39]. Furthermore, bone formation and remodelling is similar in 
zebrafish and humans, and the pathways regulating these processes are well conserved 
[37, 39-41]. As such, the zebrafish is a good model organism for human bone disor-
ders. Our zebrafish model of WS had an overt skeletal phenotype that included de-
creased bone density. Therefore, we believe our WS zebrafish model can be used for 
testing novel therapeutic strategies aimed at improving skeletal development and in-
creasing bone density. As part of the planned project mentioned above, our mutant 
fish will serve as a model to test the effect on bone development and bone density of 
existing therapeutics currently not used for this purpose. This collaboration will enable 
the development of novel therapeutic strategies addressing two common conditions. 
Due to its focus on tissue remodelling and invasion, there is considerable potential for 
spin-off into other common pathological conditions such as scarring and cancer. In 
addition, the workflow developed in the program can be applied to other (skin) disor-
ders. 
 
Conclusion 
In conclusion, studying the molecular basis of rare disorders such as Winchester syn-
drome is important for two main reasons. Firstly, providing the affected patients with 
a definite diagnosis is important to improve coping with their symptoms, focussing 
clinical follow-up examinations and offering genetic counselling. Secondly, rare disor-
ders can provide novel insights into more common pathologies. As such, the models 
used and developed in this thesis have been or will be subsequently used in academic 
and industry collaborations to develop novel therapeutic strategies for two common 
disorders: acne vulgaris and reduced bone density.  
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